A Comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats

References

• Cabal J, Bajgar J. (1999). Tabun—reappearance 50 years later (in Czech). Chem Listy 93:27–31.
   Web of Science ®Google Scholar
• Cabal J, Kuca K, Kassa J. (2004). Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase. Pharmacol Toxicol 95:81–86.
   Google Scholar
• Cassel G, Karlsson L, Waara L, Ang Wee K, Goransson-Nyberg A. (1997). Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur J Pharmacol 332:43–52.
   PubMed Web of Science ®Google Scholar
• Dawson RM. (1994). Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 14:317–331.
   PubMed Web of Science ®Google Scholar
• Dohnal V, Kuca K, Jun D. (2005). Prediction of a new broad-spectrum reactivator capable of reactivating acetylcholinesterase inhibited by nerve agents. J Appl Toxicol 3:139–145.
   Google Scholar
• Ekström F, Akfur C, Tunemalm AK, Lundberg S. (2006). Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry 45:74–81.
   PubMed Web of Science ®Google Scholar
• Frantik E, Hornychova M. (1995). Clustering of neurobehavioral measures of toxicity. Homeostasis 36:19–25.
   Google Scholar
• Hornychova M, Frantik E, Kubat J, Formanek J. (1995). Neurotoxicity profile of supermethrin, a new pyrethroid insecticide. Cent Eur J Publ Health 3:210–218.
   PubMedGoogle Scholar
• Jokanovic M. (1993). Anticholinesterase activity and delayed neurotoxic effects of tabun in hens. Vojvosanit Pregl 50:451–456.
   PubMedGoogle Scholar
• Jokanovic M, Maksimovic M, Kilibarda V, Jovanovic D, Savic D. (1996). Oxime-induced reactivation of acetylcholinesterese inhibited by phosphoramidates. Toxicol Lett 85:35–39.
   PubMed Web of Science ®Google Scholar
• Kassa J. (2002). Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 40:803–816.
   PubMed Web of Science ®Google Scholar
• Kassa J, Cabal J. (1999a). A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with currently available oximes and H oximes against soman by in vitro and in vivo methods. Toxicology 132:111–118.
   PubMed Web of Science ®Google Scholar
• Kassa J, Cabal J. (1999b). A comparison of the efficacy of acetylcholinesterase reactivators against cyclohexyl methylphosphonofluoridate (GF agent) by in vitro and in vivo methods. Pharmacol Toxicol 84:41–45.
   PubMedGoogle Scholar
• Kassa J, Cabal J, Kuca K. (2005). A comparison of the efficacy of currently available oximes against tabun in rats. Biologia 60(Suppl 17):77–79.
   Google Scholar
• Kassa J, Karasova J, Musilek K, Kuca K. (2008a). An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) with commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology 243:311–316.
   PubMed Web of Science ®Google Scholar
• Kassa J, Karasova J, Bajgar J, Kuca K, Musilek K. (2008b). A comparison of the therapeutic and reactivating efficacy of newly developed bispyridinium oximes (K206, K269) with currently available oximes against tabun in rats and mice. J Enz Inhib Med Chem 23:776–780.
   PubMed Web of Science ®Google Scholar
• Kassa J, Krejcova G. (2003). Neuroprotective effects of currently used antidotes in tabun-poisoned rats. Pharmacol Toxicol. 92:258–264.
   PubMedGoogle Scholar
• Kassa J, Kuca K, Bartosova L, Kunesova G. (2007). The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem 11:267–283.
   Web of Science ®Google Scholar
• Kuca K, Bielavsky J, Cabal J, Bielavska M. (2003a). Synthesis of a potential reactivator of acetylcholinesterase1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)-propane dibromide. Tetrahedron Lett 44:3123–3125.
   Web of Science ®Google Scholar
• Kuca K, Bielavsky J, Cabal J, Kassa J. (2003b). Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg Med Chem Lett 13:3545–3547.
   PubMed Web of Science ®Google Scholar
• Kuca K, Jun D, Musilek K. (2006). Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 6:269–277.
   PubMed Web of Science ®Google Scholar
• Marrs TC. (1993). Organophosphate poisoning. Pharmacol Ther 58:51–66.
   PubMed Web of Science ®Google Scholar
• Moser VC, Tilson H, McPhail RC, Becking GC, Cuomo V, Frantik E, Kulig BM, Winneke G. (1997). The IPCS collaborative study on neurobehavioral screening methods: II. Protocol design and testing procedures. NeuroToxicology 18:929–938.
   PubMed Web of Science ®Google Scholar
• Musilek K, Holas O, Kuca K, Jun D, Dohnal V, Opletalova V, Dolezal M. (2008). Synthesis of mono-oxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J Enz Inhib Med Chem 23:70–76.
   PubMed Web of Science ®Google Scholar
• Puu G, Artursson E, Bucht G. (1986). Reactivation of nerve agent–inhibited acetylcholinesterase by HI-6 and obidoxime. Biochem Pharmacol 35:1505–1510.
   PubMed Web of Science ®Google Scholar
• Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K, Toshibo M, Sakai I, Mukoyama H, Takatori T. (2003). Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 28:1401–1407.
   PubMed Web of Science ®Google Scholar
• Worek F, Widmann R, Knopff O, Szinicz L. (1998). Reactivating potency of obidoxime, pralidoxime, HI-6, and HLö-7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 72:237–243.
   PubMed Web of Science ®Google Scholar